KKR Genetic Disorder L.P. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-07 6:15 pm Sale |
2025-03-05 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 19,260,971 10.100% |
-6,000,000 (-23.75%) |
Filing |
| 2024-09-17 6:41 pm Sale |
2024-09-13 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 25,260,971 13.400% |
-5,800,000 (-18.67%) |
Filing |
| 2021-02-17 5:28 pm Sale |
2020-02-11 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 31,060,971 20.900% |
-3,450,000 (-10.00%) |
Filing |
| 2020-10-06 4:45 pm Unchanged |
2020-10-05 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 34,510,971 28.200% |
0 (Unchanged) |
Filing |
| 2020-06-01 5:09 pm Sale |
2020-05-28 | 13D | BridgeBio Pharma, Inc. BBIO |
KKR Genetic Disorder L.P. | 34,510,971 28.400% |
-2,389,690 (-6.48%) |
Filing |